Department of Physiology, Augusta University, GA, USA.
Clin Sci (Lond). 2022 Sep 16;136(18):1341-1346. doi: 10.1042/CS20220056.
MicroRNA (miRNA) are small, single strand non-coding RNA molecules involved in the post-transcriptional regulation of target genes. Since their discovery in 1993, over 2000 miRNAs have been identified in humans and there is growing interest in both the diagnostic and therapeutic potential of miRNA. The identification of biomarkers for human disease progression remains an active area of research, and there is a growing number of miRNA and miRNA combinations that have been linked to the development and progression of numerous cardiovascular diseases, including hypertension. In 2010, Chen et al. reported in Clinical Science that cell-free circulating miRNA could serve as novel biomarkers for acute myocardial infarction [1]. In this commentary, we expand on this topic to discuss the potential of using miRNA as biomarkers for hypertension and hypertension-related end-organ damage.
MicroRNA (miRNA) 是一种小的、单链的非编码 RNA 分子，参与靶基因的转录后调控。自 1993 年发现以来，已经在人类中鉴定出超过 2000 种 miRNA，并且对 miRNA 的诊断和治疗潜力的兴趣日益增加。寻找人类疾病进展的生物标志物仍然是一个活跃的研究领域，越来越多的 miRNA 和 miRNA 组合与许多心血管疾病（包括高血压）的发展和进展有关。2010 年，Chen 等人在《临床科学》上报告说，细胞游离循环 miRNA 可以作为急性心肌梗死的新型生物标志物[1]。在这篇评论中，我们扩展了这个主题，讨论了将 miRNA 用作高血压和高血压相关靶器官损伤的生物标志物的潜力。
